| Topic | PBC Treatment Landscape & UDCA API Demand |
|---|---|
| PBC Indication | UDCA is mandatory first-line therapy (AASLD/EASL) |
| UDCA Dose | 13-15 mg/kg/day, lifelong treatment |
| OCA Status | Withdrawn EU (Nov 2024) and US (Sep 2025) |
| New Add-Ons | Elafibranor (2024), Seladelpar (2024) — both UDCA combo |
| Market Impact | UDCA demand structurally insulated; new drugs expand market |
The primary biliary cholangitis (PBC) treatment landscape has undergone its most significant transformation in a decade. Between late 2024 and early 2026, the only second-line drug approved since 2016 was withdrawn from global markets, while two entirely new classes of PPAR agonists received regulatory approval. For pharmaceutical buyers and API procurement professionals, understanding these changes is not academic — it directly impacts UDCA demand forecasts, supply chain planning, and competitive positioning. This analysis explains what changed, why it matters, and what it means for UDCA API buyers in 2026 and beyond.
Ursodeoxycholic acid has been the cornerstone of PBC treatment for over three decades, and its position has never been stronger. Both the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) maintain UDCA at 13-15 mg/kg/day as the mandatory first-line therapy for all PBC patients upon diagnosis.
The clinical evidence supporting UDCA is overwhelming. Approximately 60-70% of PBC patients achieve an adequate biochemical response on UDCA alone, measured by normalization or significant improvement in alkaline phosphatase (ALP) and bilirubin levels — the two key prognostic markers in PBC. Patients who respond to UDCA have survival rates comparable to the general population, a finding that has been replicated across multiple long-term cohort studies spanning 20+ years of follow-up.
Critically for API buyers, UDCA's first-line status means every diagnosed PBC patient starts on UDCA and stays on UDCA for life. Second-line therapies, whether old or new, are reserved for incomplete responders — the roughly 30-40% of patients whose ALP does not normalize on UDCA monotherapy. Even these patients continue UDCA as background therapy when a second-line drug is added. This structural position makes UDCA one of the most demand-resilient APIs in the hepatology segment.
A standard PBC patient at 70 kg body weight on 15 mg/kg/day requires 1,050 mg of UDCA daily. At this dose, a single patient consumes approximately 383 grams of UDCA API per year — every year, for the remainder of their life. For a mid-sized generic manufacturer serving 50,000 PBC patients, that translates to roughly 19 metric tons of UDCA API annually from PBC alone, before accounting for gallstone dissolution and other indications. The math is straightforward: as PBC diagnosis rates rise, UDCA volume requirements rise in lockstep.
Obeticholic acid (OCA), marketed as Ocaliva by Intercept Pharmaceuticals, was approved by the FDA in 2016 as a second-line treatment for PBC patients with inadequate response to UDCA. For nearly eight years, it was the only option beyond UDCA. That changed dramatically between November 2024 and September 2025.
The European Commission revoked Ocaliva's marketing authorization in November 2024, following a recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). The CHMP concluded that the benefit-risk balance of OCA was no longer favorable, citing post-marketing safety data that showed higher rates of serious hepatic adverse events than were evident at the time of the original conditional approval. The revocation was effective across all EU/EEA member states.
On September 11, 2025, Intercept Pharmaceuticals voluntarily withdrew Ocaliva from the US market at the FDA's request. The FDA had been reviewing post-marketing safety data that raised concerns about liver injury risk in PBC patients without cirrhosis — the very population for whom OCA was indicated. Rather than litigate the FDA's findings or accept additional restrictive labeling, Intercept chose to withdraw the product entirely from the US market.
The removal of OCA from both major Western markets created a brief therapeutic gap. Between the last OCA prescriptions being filled and the approval of new second-line options, UDCA-incomplete responders had no approved add-on therapy. This gap has since been addressed by the new PPAR agonists, but the episode carries three important lessons for UDCA API buyers:
With OCA withdrawn, two new second-line therapies — both PPAR agonists — received regulatory approval in 2024, filling the therapeutic gap. Their label language is consistent and unambiguous: both are indicated in combination with UDCA for patients with inadequate response to UDCA alone. Neither is approved as monotherapy.
| Drug | Brand Name | Mechanism | Approval Year | Pivotal Trial | Primary Endpoint Met |
|---|---|---|---|---|---|
| Elafibranor | Iqirvo | Dual PPAR-α/δ agonist | 2024 | ELATIVE | 51% vs 4% placebo (composite ALP endpoint) |
| Seladelpar | Livdelzi | Selective PPAR-δ agonist | 2024 | RESPONSE | 61.7% vs 20% placebo (composite ALP endpoint) |
Elafibranor is a dual PPAR-α/δ agonist developed by Ipsen (following acquisition from Genfit). The ELATIVE trial demonstrated that 51% of patients on elafibranor plus UDCA achieved the composite biochemical response endpoint (ALP <1.67x ULN with ≥15% reduction, plus normal bilirubin) compared to 4% on placebo plus UDCA — a statistically significant difference. Elafibranor's dual mechanism addresses both cholestasis (via PPAR-α) and inflammation/fibrosis (via PPAR-δ), but the clinical relevance of these mechanistic differences versus selective PPAR-δ agonism remains an area of ongoing study.
Seladelpar is a selective PPAR-δ agonist developed by Gilead Sciences (following acquisition of CymaBay Therapeutics). The RESPONSE trial showed that 61.7% of patients on seladelpar plus UDCA met the composite biochemical response endpoint, versus 20% on placebo plus UDCA. A notable differentiating feature: seladelpar demonstrated statistically significant improvement in pruritus (itch), the most burdensome symptom for many PBC patients. This contrasts with OCA, which was known to worsen pruritus — a tolerability issue that contributed to its market difficulties.
The launch of elafibranor and seladelpar should be read as validation of UDCA's irreplaceable role, not as a threat to it. Both drugs studied their efficacy in patients who remained on UDCA. Their regulatory labels require co-administration with UDCA. Their commercial success depends on the size of the PBC-treated population, the overwhelming majority of whom are on UDCA. For UDCA API buyers, this means the addressable market expands with every new PBC drug approval — because every new drug brings more patients into the treatment system, and every treated patient consumes UDCA.
The structural demand drivers for UDCA API are unusually robust. They can be broken down into three layers, each of which operates independently of changes in the second-line therapy landscape.
Global PBC incidence is estimated at 2-4 per 100,000 person-years, with prevalence ranging from approximately 20-40 per 100,000 in Western populations. Two secular trends are pushing these numbers higher: improved diagnostic awareness (more patients identified through routine liver enzyme screening) and an aging global population (PBC predominantly affects women over 40, with peak incidence in the fifth and sixth decades of life). In markets with established UDCA access, diagnosed prevalence has been growing at an estimated 3-5% annually over the past decade — a trend that demographic projections suggest will persist through at least 2035.
PBC is a chronic, progressive autoimmune liver disease. Once diagnosed, treatment is lifelong. A patient diagnosed at age 50 who starts UDCA at 1,000 mg/day will, over a 30-year treatment horizon, consume approximately 11 kilograms of UDCA API. Multiply this by a global diagnosed PBC population estimated in the hundreds of thousands, and the base-load demand for UDCA API becomes not just large but highly predictable — a characteristic that is rare in the pharmaceutical API market and highly valued by procurement planners.
This is the core insight for API buyers. The second-line PBC therapy landscape has seen three major perturbations since 2024: OCA's withdrawal, elafibranor's approval, and seladelpar's approval. None of these events reduced UDCA consumption. They either had zero impact on UDCA volume (OCA withdrawal, since OCA was an add-on) or increased it (new drug approvals expand the treated patient pool, all of whom consume UDCA). The table below summarizes the demand impact of each event:
| Event | Timing | Impact on UDCA API Demand | Rationale |
|---|---|---|---|
| OCA EU withdrawal | Nov 2024 | Neutral | OCA was add-on to UDCA; patients continued UDCA |
| OCA US withdrawal | Sep 2025 | Neutral to slightly positive | Some OCA-intolerant patients may have discontinued OCA but remained on UDCA monotherapy |
| Elafibranor approval | 2024 | Positive | Expands treated population; label requires UDCA co-administration |
| Seladelpar approval | 2024 | Positive | Expands treated population; label requires UDCA co-administration |
The withdrawal of OCA removes a drug that some market observers once speculated might eventually challenge UDCA's first-line position in certain subpopulations. That speculation never materialized — OCA's label always required UDCA co-administration for PBC — but the withdrawal eliminates even the hypothetical competitive threat. UDCA's status as the irreplaceable foundation of PBC treatment is more secure in 2026 than at any point in the past decade.
For UDCA API buyers — generic manufacturers, formulation developers, hospital group purchasing organizations, and distributors — the 2026 PBC treatment landscape carries several actionable implications.
UDCA API demand is structurally growing and structurally insulated from therapeutic substitution. This combination — growing demand plus low substitution risk — makes UDCA a premium API category where supply security is more valuable than marginal price negotiation. Buyers who lock in multi-year supply agreements with qualified, multi-certified manufacturers (those holding both CEP and US DMF) position themselves to capture volume growth without supply interruption risk.
The addition of elafibranor and seladelpar to the treatment landscape will increase the number of PBC patients under active specialist care, which in turn increases UDCA prescribing. A manufacturer producing 50 metric tons of UDCA API annually may need to scale to 65-75 metric tons within five years to meet growing demand. When auditing suppliers, ask specifically about production capacity expansion plans, synthetic route scalability, and cholic acid starting material sourcing strategy — these are the constraints that will differentiate reliable long-term partners from capacity-constrained suppliers.
Several regulatory developments could further expand UDCA demand in the medium term: (1) China's ongoing healthcare reform and expanding PBC diagnosis rates could open a significant new demand center; (2) the potential for UDCA to receive formal regulatory endorsement as a preventive therapy for PBC in high-risk populations (e.g., first-degree relatives with positive AMA); (3) the exploration of UDCA in combination with PPAR agonists as a potential first-line dual therapy, which would increase per-patient UDCA dosing intensity. None of these are certain, but each would represent a step-change increase in UDCA API demand.
While PBC is the largest single indication for UDCA, it is not the only one. UDCA is also indicated for gallstone dissolution (typically 8-10 mg/kg/day), and its use in other cholestatic conditions — primary sclerosing cholangitis (off-label but common), intrahepatic cholestasis of pregnancy, and pediatric cholestatic disorders — adds further volume. Buyers serving multiple therapeutic markets benefit from UDCA's diversified indication base, which smooths demand across regulatory and competitive cycles in any single indication.